GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient with Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02)

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Alveolar Soft Part Sarcoma
Interventions
BIOLOGICAL

GCAR1

GCAR 1 is a patient-specific cell therapy product containing a mixture of autologous lymphocytes transduced with a lentiviral vector containing a chimeric antigen receptor (CAR) that enables the specific targeting towards tumor cells expressing the cell surface protein glycoprotein non-metastatic B (GPNMB).

All Listed Sponsors
lead

AHS Cancer Control Alberta

OTHER